Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Moodys
Harvard Business School
Colorcon
Medtronic

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,858,070

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,858,070
Title:Multivalent immunoglobulin-based bioactive assemblies
Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:12/396,605
Patent Claims:1. A method of delivering a diagnostic or therapeutic agent comprising: a) obtaining a stably tethered structure comprising at least one diagnostic or therapeutic agent, wherein the stably tethered structure comprises (i) an IgG antibody that binds to tumor-associated antigen wherein the antibody is attached to two AD anchor domain) moieties and (ii) four copies of a cytokine, each cytokine attached to a DDD (dimerization and docking domain) moiety, wherein the AD moiety has the peptide sequence from an anchoring domain of an AKAP (A-kinase anchoring protein) selected from the group consisting of AD1 (SEQ ID NO: 3) and AD2 (SEQ ID NO: 4) and the DDD moiety has the peptide sequence from a dimerization and docking domain of protein kinase A selected from the group consisting of DDD1 (SEQ ID NO: 1) and DDD2 (SEQ ID NO: 2); and b) administering the stably tethered structure to a subject.

2. The method of claim 1, wherein the DDD moieties bind to each other to form dimers and each AD moiety binds to a dimer of DDD moieties.

3. The method of claim 1, wherein the cytokines are selected from the group consisting of G-CSF, interferon-.beta.1A, interferon-.alpha.2b and erythropoietin.

4. The method of claim 1, wherein the a tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, BrE3-antigen, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20O, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin-like growth factor-1 (ILGF-1), ILGF-1 receptor, KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific for PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis factor-.alpha., tumor necrosis factor-.beta., VEGF, ED-B fibronectin, and 17-1A antigen.

5. The method of claim 1, wherein the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a cytokine, a chemokine, an anti-angiogenic agent, an apoptotic agent, a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, an antibiotic, an antibody, an antibody fragment and a hormone.

6. The method of claim 1, wherein the IgG antibody is selected from the group consisting of LL1 (anti-CD74), LL2 (anti-CD22), RFB4 (anti-CD22), A20 (anti-CD20), L243 (anti-HLA class II), CC49 (anti-TAG-72), MN-14 (anti-CEA), MN-15 (anti-CEA), 679 (anti-HSG), 734 (anti-In-DTPA), L19 (anti-ED-B fibronectin), R1 (anti-IGF-1R), PAM4 (anti-MUC1), RS7 (anti-EGP-1), adalimumab, infliximab, omalizumab and palivizumab.

7. The method of claim 1, wherein the antibody is a human, humanized or chimeric antibody.

8. The method of claim 1, wherein the diagnostic agent is selected from the group consisting of a radioisotope, an imaging agent, a dye, an enzyme, a fluorescent agent, a chemiluminescent agent, a bioluminescent agent, a paramagnetic ion and an ultrasound label.

9. A method of treating B cell leukemia or B cell lymphoma comprising: a) obtaining a stably tethered structure comprising at least one therapeutic agent, wherein the stably tethered structure comprises (i) an IgG antibody that binds to tumor associated antigen wherein the antibody is attached to two AD moieties and (ii) four copies of a or cytokine, each or cytokine attached to a DDD moiety, wherein the AD moiety has the peptide sequence from an anchoring domain of an AKAP (A-kinase anchoring protein) selected from the group consisting of AD1 (SEQ ID NO: 3) and AD2 (SEQ ID NO: 4) and the DDD moiety has the peptide sequence from a dimerization and docking domain of protein kinase A selected from the group consisting of DDD1 (SEQ ID NO: 1) and DDD2 (SEQ ID NO: 2); and b) administering the stably tethered structure to a subject with cancer.

10. The method of claim 9, wherein the cytokines are selected from the group consisting of G-CSF, interferon-.beta.1A, interferon-.alpha.2b and erythropoietin.

11. The method of claim 9, wherein the tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, BrE3-antigen, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin-like growth factor-1 (ILGF-1), ILGF-1 receptor, KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific for PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis factor-.alpha., tumor-necrosis factor-.beta., VEGF, ED-B fibronectin, and 17-1A-antigen.

12. The method of claim 11, further comprising administering a chemotherapeutic agent, a cytokine, radiation therapy, immunotherapy, radioimmunotherapy, localized hyperthermia, laser irradiation, an anti-angiogenic agent or surgical excision in combination with the stably tethered structure.

Details for Patent 7,858,070

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1974-01-15 ⤷  Try it Free 2025-10-19
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1984-12-27 ⤷  Try it Free 2025-10-19
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1985-02-15 ⤷  Try it Free 2025-10-19
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1990-02-16 ⤷  Try it Free 2025-10-19
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 1974-03-26 ⤷  Try it Free 2025-10-19
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 1973-03-05 ⤷  Try it Free 2025-10-19
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 1998-06-19 ⤷  Try it Free 2025-10-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
McKinsey
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.